E79.0

Hyperuricemia without signs of inflammatory arthritis and tophaceous disease

Hyperuricemia without signs of inflammatory arthritis and tophaceous disease, often referred to as asymptomatic hyperuricemia, is a biochemical condition characterized by an abnormally high level of uric acid in the blood (typically defined as serum urate levels greater than 6.8 or 7.0 mg/dL) in the absence of clinical gout symptoms, such as acute arthritis or visible tophi. Uric acid is the final oxidation product of purine metabolism in humans. While many individuals with elevated serum urate levels never develop clinical gout, the condition represents a precursor state to gouty arthritis and is associated with the deposition of monosodium urate crystals in joints and tissues. Chronic hyperuricemia is also clinically significant due to its association with metabolic syndrome, hypertension, chronic kidney disease, and an increased risk of uric acid nephrolithiasis (kidney stones). Management typically focuses on addressing underlying causes, such as diet or medications, and monitoring for the transition to symptomatic disease.

Clinical Symptoms

  • Elevated serum urate levels (biochemical finding)
  • Absence of joint pain
  • Absence of joint swelling or erythema
  • Absence of palpable tophi (urate crystal deposits)
  • Possible renal colic (if associated with uric acid stones)
  • Hematuria (if associated with uric acid stones)
  • Occasional flank pain related to crystalluria

Common Causes

  • Renal underexcretion of uric acid (most common cause, often due to genetic variants in transporters like SLC22A12 or SLC2A9)
  • Purine overproduction (endogenous)
  • High-purine dietary intake (e.g., organ meats, seafood, red meat)
  • Excessive alcohol consumption, particularly beer and spirits
  • Excessive fructose intake (e.g., high-fructose corn syrup)
  • Obesity and metabolic syndrome
  • Chronic kidney disease (impaired clearance)
  • Diuretic therapy (e.g., thiazides and loop diuretics)
  • Use of low-dose aspirin or cyclosporine
  • Rapid cell turnover conditions (e.g., psoriasis, hemolytic anemia, or lymphoproliferative disorders)
  • Hypothyroidism

Documentation & Coding Tips

Explicitly exclude the presence of inflammatory arthritis or tophaceous disease to validate the use of E79.0.

Example: Patient presents for follow-up of lab results indicating a serum urate of 9.4 mg/dL. Physical examination confirms the complete absence of joint swelling, tenderness, erythema, or warmth in the first metatarsophalangeal joints, ankles, and knees. No subcutaneous tophi or evidence of chronic urate crystal deposition observed on physical inspection. Diagnosis: Hyperuricemia without signs of inflammatory arthritis (E79.0). The patient also has documented Stage 2 Chronic Kidney Disease (N18.2), which increases the complexity of monitoring.

Billing Focus: Verification of asymptomatic status through negative physical exam findings for joint involvement.

Document the underlying etiology or contributing factors such as diet, medication, or renal insufficiency.

Example: 65-year-old male with persistent hyperuricemia (E79.0), currently asymptomatic. Elevation likely secondary to use of Hydrochlorothiazide 25mg daily for Essential Hypertension (I10) and moderate alcohol intake. Serum uric acid remains at 8.8 mg/dL. Given the patient history of renal calculi (N20.0), treatment is initiated to prevent further stone formation despite lack of joint symptoms.

Billing Focus: Causality and associated conditions including medication-induced hyperuricemia.

Note the absence of renal calculi if applicable, as asymptomatic hyperuricemia is distinct from urolithiasis.

Example: Follow-up for lab-detected hyperuricemia (E79.0). Serum urate 9.1 mg/dL. No history of flank pain or hematuria. Renal ultrasound was negative for nephrolithiasis. Patient remains clinically asymptomatic with no tophaceous deposits and no history of podagra. Plan involves low-purine diet and weight management for Obesity (E66.9).

Billing Focus: Diagnostic specificity excluding secondary manifestations like renal stones.

Distinguish between primary and secondary hyperuricemia for more accurate metabolic profiling.

Example: Patient with Essential Hypertension (I10) and asymptomatic hyperuricemia (E79.0). Serum uric acid 8.5 mg/dL. No clinical signs of acute gouty arthritis. Diagnosis is primary hyperuricemia likely related to metabolic syndrome components including BMI of 32 (E66.9). Discussed long-term risks of cardiovascular events.

Billing Focus: Proper categorization as a primary metabolic disorder versus a symptom of another acute process.

Incorporate the rationale for treatment in the absence of symptoms, such as high cardiovascular risk or severe levels.

Example: Asymptomatic hyperuricemia (E79.0) with serum uric acid level of 12.0 mg/dL. Although the patient has no history of gouty flares, the extreme elevation warrants intervention with Allopurinol 100mg daily to mitigate risk of sudden urate nephropathy and chronic renal decline. Patient also monitored for Type 2 Diabetes (E11.9).

Billing Focus: Documentation of therapeutic necessity for an otherwise asymptomatic condition.

Relevant CPT Codes

Related Diagnoses

Hierarchy